RBC Capital analyst Ryan Halsted resumed coverage of Sotera Health (SHC) with an Outperform rating and $24 price target Sotera Health is viewed positively due to strong fundamentals and one of the highest margin profiles in coverage, the analyst tells investors in a research note. Its end-to-end sterilization services, supported by a defensible capacity moat in a growing medical device market, underpin sustainable high-single-digit growth and modest margin expansion, the firm adds.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health upgraded to Overweight from Neutral at Piper Sandler
- Sotera Health initiated with an Outperform at William Blair
- Sotera Health: Integrated Market Leadership, Easing Litigation Overhang, and Valuation Upside Support Buy Rating
- Sotera Health 16.2M share Block Trade priced at $16.50
- BMO Capital’s Buy Rating on Sotera Health: Positive Outlook Amid Growth Resurgence and Strategic Strengths